UNSPSC 85881723: Nonimaging nuclear medicine probe of pelvic lymphatics using technetium 99m (tc-99m)

This classification denotes the group of activities that yields an intervention or procedure of nonimaging nuclear medicine probe of pelvic lymphatics using technetium 99m (tc-99m). This intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code C75D1ZZ

UNSPSC 85881723 Nonimaging nuclear medicine probe of pelvic lymphatics using technetium 99m (tc-99m) is a Commodity code for a specific radiopharmaceutical diagnostic imaging agent; however, recent state and local procurement activity does not support actual buying under this code. The three most recent opportunities posted under or near this code's classification—San Mateo Medical Center's diagnostic imaging PACS system RFP (due October 21, 2026), Birdville Independent School District's special education contracted services RFP (due October 21, 2026), and Santa Clara Health System's temporary health professional staffing services RFSQ (due October 7, 2026)—address enterprise imaging software, school support services, and clinical staffing respectively, none of which align with procurement of radiopharmaceutical imaging agents. The code shows no discernible recent activity in state and local government buying patterns, and the opportunities attributed to it appear to reflect tagging mismatches rather than legitimate demand signals under this Commodity classification.

The absence of recent opportunities in this code's actual scope—radiopharmaceutical procurement for nuclear medicine imaging—signals limited or no current state and local government solicitation activity. Public hospital systems and health departments that would be the primary users of such agents do not appear to be posting RFPs, RFQs, or ITBs for tc-99m radiopharmaceuticals in the current procurement cycle. Business development efforts targeting this Commodity code should verify whether state and local health systems source these materials through group purchasing organizations, standing national contracts, or direct manufacturer relationships rather than through formal competitive procurement notices.